{"id":"W2983220476","doi":"10.1182/blood-2019-122637","title":"Overall and Progression Free Survival from the Mcrn-003/Myx.1 Trial: A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa; London Health Sciences Centre; Hôtel-Dieu de Québec; Saint John Regional Hospital; Princess Margaret Cancer Centre; University of New Brunswick; Université de Montréal; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Carfilzomib; Medicine; Clinical endpoint; Lenalidomide; Internal medicine; Dexamethasone; Oncology; Multiple myeloma; Cyclophosphamide; Progression-free survival; Phases of clinical research; Clinical trial; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003577091,0.001437139,0.001698877,0.0004061564,0.0005510072,0.001002552,0.000946635,0.001440382,0.004223554],"category_scores_gemma":[0.001331374,0.0004591499,0.001332721,0.0003015469,0.0008580188,0.0006909588,0.0004724771,0.003775763,0.0006320884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001327864,"about_ca_system_score_gemma":0.002623871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001612115,"about_ca_topic_score_gemma":0.004848798,"domain_scores_codex":[0.9993244,0.0003666052,0.00002529291,0.00009203993,0.00007458464,0.0001170897],"domain_scores_gemma":[0.9989594,0.0001437931,0.0001935955,0.00006943214,0.00005848852,0.0005752578],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.917591,0.02408999,0.002720693,0.0008242177,0.0007413899,0.0001064931,0.0001638296,0.001387046,0.009307059,0.0002223661,0.004566617,0.03827924],"study_design_scores_gemma":[0.8268032,0.1628215,0.005911894,0.0000417641,0.0004575785,0.0001127788,0.00002034669,0.0007539515,0.0009659497,0.0001958472,0.001896429,0.00001870756],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831972,0.003748045,0.0004579349,0.001134619,0.0001945539,0.005369827,0.001964523,0.0001168832,0.003816463],"genre_scores_gemma":[0.9809998,0.001952599,0.001678928,0.001305802,0.0003240126,0.005979005,0.003472762,0.00003670905,0.004250178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004223554,"threshold_uncertainty_score":0.01891768,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0364345625487363,"score_gpt":0.3139965638600113,"score_spread":0.2775620013112751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}